Pregabalin is an ion channel modulator used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its product, LYRICA was originally developed by Pfizer Ltd.
LYRICA was launched in China in 2010 and has been approved for the treatment of postherpetic neuralgia. In 2018, it was approved for the fibromyalgia indication. Subsequently, some generic pregabalin drugs were launched in China one after another.
In 2019, pregabalin (trade name: Laireike), produced by Chongqing Saiwei Pharmaceutical, was approved for the treatment of partial-onset epilepsy in adults, adding a new indication for pregabalin to the Chinese market. In 2020, pregabalin was included in Chinese class B medical insurance, and there are three manufacturers in the Chinese market, of which Pfizer Ltd is the main manufacturer.
According to the market research, the sales value of pregabalin in the Chinese market increased year by year from 2016 to 2020. Among them, the sales value growth in 2019 was the most obvious. The sales value of pregabalin reached CNY 143 million in 2019, with an annual growth rate of 57.19%.
The main reason is that pregabalin was approved for new indications in China from 2018 to 2019, and the NMPA lifted the restriction on medical insurance indications of pregabalin in 2019, resulting in a substantial increase in its volume and its sales value. In 2020, the sales value of pregabalin in the Chinese market is about CNY 186 million. The CAGR in value of sales of Pregabalin from 2016 to 2020 is 40.55%.
The analyst expects that with the addition of new companies, the sales volume and market scale of Pregabalin in China market will continue to increase from 2021 to 2025.
According to the analyst’s market research, in the first half of 2021, more than 20 companies in China are applying for generic pregabalin drugs, including Jiangsu Hengrui Pharmaceutical Co., Ltd., Xuzhou Enhua Pharmaceutical Co., Ltd. and Sichuan Kelun Pharmaceutical Co., Ltd.
In addition, China has approved for marketing 3 indications of pregabalin, and a total of 4 indications have been approved for marketing globally. Therefore, the number of pregabalin indications in China is likely to increase, and the value and sales volume will increase in the future.
The impact of COVID-19 on the Chinese pregabalin market
Pregabalin sales value in China 2016-2020
Competitive Landscape of China Pregabalin Market
Pregabalin price in China
Pregabalin Price in China by Regions and Manufacturers
Analysis of factors affecting the development of the Chinese pregabalin market
China Pregabalin Market Outlook 2021 to 2025
Main topics covered:
1 Relevant Concepts of Pregabalin
1.1 Pregabalin Indications
1.2 Pregabalin Development in China
1.3 Government Approval of Pregabalin in China
1.4 The impact of COVID-19 on Pregabalin Sales in China
2 China Pregabalin Sales, 2016-2020
2.1 Pregabalin Sales Value
2.1.1 Overall sales value
2.1.2 Sales Value by Region
2.2 Pregabalin Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 China Pregabalin Sales by Dosage Form, 2016-2020
2.3.2 Analysis of other dosage forms
3 Analysis of Pregabalin Key Manufacturers in China in 2020
3.1 Pregabalin Key Manufacturers Market Share Analysis
3.1.1 Market Share Survey by Sales Value
3.1.2 Market Share Survey by Sales Volume
3.2 Pfizer SA
3.2.1 Company profile
3.2.2 China LYRICA (Pregabalin by Pfizer Ltd) Sales
3.3 Chongqing Saiwei Pharmaceutical Co., Ltd.
3.3.1 Company Profile
3.3.2 China Laireike (Chongqing Saiwei Pharmaceutical Co., Ltd. Pregabalin) Sales
3.4 Qilu Pharmaceutical (Hainan) Co., Ltd.
3.4.1 Company Profile
3.4.2 China Xisiping (Qilu Pharmaceutical (Hainan) Co., Ltd. Pregabalin) Sales
4 Pregabalin Price for Different Manufacturers in China, 2020-2021
4.1 Pfizer Ltd (LYRICAL)
4.2 Chongqing Saiwei Pharmaceutical Co., Ltd. (Laireike)
4.3 Qilu Pharmaceutical (Hainan) Co., Ltd. (Xisiping)
5 China Pregabalin Drugs Market Outlook, 2021-2025
5.1 Influencing Factors of China Pregabalin Market Development
5.1.1 The impact of COVID-19 on the China Pregabalin Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast
For more information on this report, visit https://www.researchandmarkets.com/r/4tyrov
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220310005700/en/
Laura Wood, Senior Press Officer
For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900